SEARCH

SEARCH BY CITATION

References

  • 1
    Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556562.
  • 2
    Sugimoto K, Ikeda F, Stadanlick J, Nunes FA, Alter HJ, Chang KM. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex-vivo in persistent HCV infection. HEPATOLOGY 2003; 38: 14371448.
  • 3
    Rosen HR, Weston SJ, Im K, Belle SH for the Virahep-C study group. Ethnicity and the cellular immune response in patients with chronic hepatitis C genotype 1 (abstract). HEPATOLOGY 2004; 40(Suppl 1): 178A.
  • 4
    Wiley TE, Brown J, Chan J. Hepatitis C infection in African Americans: its natural history and histological progression. Am J Gastroenterol 2002; 97: 700706.
    Direct Link:
  • 5
    Crosse K, Umeadi OG, Anania F, Laurin J, Papadimitriou J, Drachenberg C, et al. Racial differences in liver inflammation and fibrosis related to chronic hepatitis C. Clin Gastroenterol Hepatol 2004; 2: 463468.
  • 6
    Sterling RK, Stravitz RT, Luketic VA, Sanyal AJ, Contos MJ, Mills AS, et al. A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans. Clin Gastroenterol Hepatol 2004; 2: 469473.
  • 7
    Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in Blacks and non-Hispanic whites. N Eng J Med 2004; 350: 22652271.
  • 8
    Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a and ribavirin for black American Patients with chronic HCV genotype 1. HEPATOLOGY 2004; 39: 17021708.
  • 9
    Strader DB, Wright T, Thomas DL, Seeff LB. AASLD practice guideline: Diagnosis, management, and treatment of hepatitis C. HEPATOLOGY 2004; 39: 11471171.
  • 10
    Fontana RJ, Lok ASF. Noninvasive monitoring of patients with chronic hepatitis C. HEPATOLOGY 2002; 36: S57S64.
  • 11
    Rosenberg WMC, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127: 17041713.
  • 12
    Patel K, Gordon SC, Jacobson I, Hezode C, Oh E, Smith KM, et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients J Hepatol 2004; 41: 934942.
  • 13
    Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. HEPATOLOGY 2003; 38: 481492.
  • 14
    Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. HEPATOLOGY 2002; 36: 986992.
  • 15
    Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. HEPATOLOGY 2003; 38: 518526.
  • 16
    Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343350.
  • 17
    Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with chronic hepatitis C, genotype 1. Gastroenterology 2006 (in press).
  • 18
    Perumalswami P, Kleiner DE, Lutchman G, Heller T, Borg B, Park Y, et al. Steatosis and fibrosis progression in untreated patients with chronic hepatitis C infection. HEPATOLOGY 2006; 43: 780787.
  • 19
    Wang CS, Wang ST, Change TT, Yao WJ, Chou P. Smoking and alanine aminotransferase levels in hepatitis C virus infection. Arch Intern Med 2002; 162: 811815.
  • 20
    Ishak K, Baptista A, Bianchi L, Callea F, DeGroote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696699.
  • 21
    The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic Hepatitis C. HEPATOLOGY 1994; 20: 1520.
  • 22
    Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis: Relationship to cirrhosis. Gastroenterology 1988; 95: 734739.
  • 23
    Giannini E, Risso D, Botta F, Chiarbonello B, Fasoli A, Malfatti F, et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med 2003; 163: 218224.
  • 24
    Bonacini M, Hadi G, Govindarajan S, Lindsay KL. Utility of discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1997; 92: 13021304.
  • 25
    Poynard T, Bedossa P. Metavir and Clinivir cooperative study groups. Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. J Viral Hepat 1997; 4: 199208.
  • 26
    Pohl A, Behling C, Oliveer D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels and platelet counts a predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastrenterol 2001; 96: 31423146.
    Direct Link:
  • 27
    Assy N, Minuk GY. Serum aspartate but not alanine aminotransferase levels help to predict the histological features of chronic hepatitis C viral infection in adults. Am J Gastroenterol 2000; 95: 15451550.
    Direct Link:
  • 28
    R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2004. Available at: http://www.R-project.org.
  • 29
    DeLong E, DeLong D, Clarke-Pearson D. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837845.
  • 30
    Colloredo G, Guido M, Sonzongni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the simple the milder the disease. J Hepatol 2003; 39: 239244.
  • 31
    Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. HEPATOLOGY 2003; 38: 14491457.
  • 32
    Imbert-Bismut F, Ratziu V, Peironi L, Charlotte F, Benhamou Y, Poynard T, MULTIVIRC group. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 10691075.
  • 33
    Conjeevaram HS, Kleiner DE, Everhart JE, Afdhal N, Brown RS, Fried MW, et al. Race, insulin resistance, visceral adiposity and hepatic steatosis in patients with chronic hepatitis C (abstract). HEPATOLOGY 2004; 40(Suppl 1): A643.
  • 34
    Hourigan LF, MacDonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. HEPATOLOGY 1999; 29: 12151219.
  • 35
    Romero-Gomez M, Viloria MDM, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriguez CM, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636641.
  • 36
    Pantsari MW, Harrison SA. Non-alcoholic fatty liver disease presenting with an isolated elevated alkaline phosphatase (abstract). Gastroenterology 2005; 128; T1748.
  • 37
    Browning JD, Kumar S, Saboorian MH, Thiele DL. Ethnic differences in the prevalence of cryptogenic cirrhosis. Amer J Gastroenterol 2004; 99: 292298.
    Direct Link:
  • 38
    Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase acitivity in the United States. Gastroenterology 2003; 124: 171179.
  • 39
    Poynard T, Bedossa P, Opolon P, and for the OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825832.
  • 40
    Poynard T, Ratziu V, Kim N, Deuffic-Burban S. Age and gender will survive to competing risks as fibrosis factors. Gastroenterology 2005; 128; 519520.
  • 41
    Kamimoto Y, Horiuchi S, Tanase S, Morino Y. Plasma clearance of intravenously injected aspartate aminotransferase enzymes: evidence for preferential uptake by sinusoidal liver cells. HEPATOLOGY 1985; 5: 367375.
  • 42
    Okuda M, Li K, Beard MR, Showalter LA, Scholle F, Lemon SM, et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002; 122: 366375.
  • 43
    Adinolfi LE, Giordano MG, Andreana A, Tripodi MF, Utili R, Cesaro G, et al. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. Br J Haematol 2001; 113: 590595.
  • 44
    Kawasaki T, Takeshita A, Souda K, Kobayashi Y, Kikuyama M, Suzuki F, et al. Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis. Am J Gastroenterol 1999; 94: 19181922.
    Direct Link:
  • 45
    Lok AS, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, et al. Predicting cirrhosis in patients with hepatitis c based on standard laboratory tests: results of the HALT-C Cohort. HEPATOLOGY 2005; 42: 282292.
  • 46
    Iacobellis A, Mangia A, Leandro G, Clemente R, Festa V, Attino V, et al. External validation of biochemical indices for non-invasive evaluation of liver fibrosis in HCV chronic hepatitis. Am J Gastroenterol 2005; 100: 868873.
    Direct Link:
  • 47
    Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. HEPATOLOGY 2003; 38: 481492.
  • 48
    Naveau S, Raynard B, Ratziu V, Abella A, Imbertbismut F, Messous D, et al. Biomarkers for the prediction of liver fibrosis in patients with alcoholic liver disease J Clin Gastroenterol Hepatol 2005; 3: 167174.
  • 49
    Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343350.